Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.60 |
| ▸ | EP300 | Q09472 | 2/20 | 0.60 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.60 |
| ▸ | SOX18 | P35713 | 1/20 | 0.54 |
| ▸ | BID | P55957 | 7/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.52 |
| ▸ | BAK1 | Q16611 | 6/20 | 0.52 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 3/20 | 0.43 |
| ▸ | F3 | P13726 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574679 | 0.79 | KAT8 (0.69) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL21530605 | 0.79 | BID (0.79) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL23683089 | 0.78 | KAT8 (0.57) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL20771694 | 0.75 | KAT8 (1.00) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL25049929 | 0.73 | CA12 (0.52) | KAT8EP300KAT5BIDMCL1 | |
| SCHEMBL4963083 | 0.73 | BID (0.55) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL20781123 | 0.72 | KAT8 (0.60) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL16431334 | 0.71 | BID (0.71) | KAT8EP300KAT5BIDMCL1 | |
| SCHEMBL2129140 | 0.71 | BID (0.76) | KAT8EP300KAT5SOX18BID | |
| SCHEMBL20333017 | 0.70 | SOX18 (1.00) | KAT8EP300KAT5SOX18BID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20200253932-A1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | THE JOHNS HOPKINS UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253932-A1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | HDAC1, HDAC11, HDAC7 | KAT8 49/4885EP300 4/4885KAT5 52/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KAT8 1592/4885EP300 1842/4885KAT5 2094/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KAT8 839/4885EP300 447/4885KAT5 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.